Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

Ian N. Fleming, Morag Hogben, Sheelagh Frame, Steven J. McClue, Simon R. Green

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.
    Original languageEnglish
    Pages (from-to)4326-35
    Number of pages10
    JournalClinical Cancer Research
    Volume14
    Issue number13
    DOIs
    Publication statusPublished - 1 Jul 2008

    Keywords

    • Animals
    • Antineoplastic Agents
    • Cell Line, Tumor
    • Cyclin D1
    • Drug Synergism
    • Female
    • Gene Expression Regulation, Neoplastic
    • Humans
    • Inhibitory Concentration 50
    • Mice
    • Models, Biological
    • Mutation
    • Neoplasm Transplantation
    • Purines
    • Receptor, erbB-2

    Fingerprint Dive into the research topics of 'Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents'. Together they form a unique fingerprint.

  • Cite this